top of page

Latest News

03/04/2025

We have received an assignment of a patent for the treatment of refractory cancer (pancreatic cancer, etc.) with three existing pharmaceuticals.

The results of an investigator-initiated clinical trial in which two (Nivolumab + Metformin) of the three drugs described in the patent were administered have showed survival of more than 7 years in a patient among advanced pancreatic cancer （Sato R, Hotta K, Kubo T, et al. (February 14, 2025) Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. Cureus 17(2). We are going to license the treatment method using the three-drug administration described in the patent to medical institutions from now on.

LINK

02/14/2025

Our headquater has moved with business expansion.

LINK

12/19/2024

Interview with CEO Yasuyuki Ishii about Japanese cedar pollen allergy was puplished in Jomo newspaper.

LINK

01/11/2024

Our president and CEO, Yasuyuki Ishii, spoke at 20th Japanese society of CART Meeting on Dec. 9th, 2023.

LINK

11/21/2023

Our president and CEO, Yasuyuki Ishii, speak at 20th Japanese society of CART online Meeting on Dec. 9th, 2023.

LINK

10/05/2023

Our president and CEO, Yasuyuki Ishii, spoke at the Tokyo Tech Open innovation.

LINK

05/01/2023

We've redesigned our website.

LINK

01/15/2023

Our headquater has moved with business expansion.

LINK

10/04/2022

English web page has been opend.

LINK

09/01/2022

Service web page has been opend.

LINK

06/28/2022

Accellvecs was certified as Tokyo Tech Venture​ by Tokyo Institute of Technology.

LINK

Accellvecs

5-59-5 Yoyogi, Shibuya-ku,

Tokyo 151-0053 Japan

©2023 Accellvecs.Inc

bottom of page